Stocks and Investing Stocks and Investing
Mon, November 9, 2020

Andrew Fein Maintained (BIIB) at Strong Buy with Decreased Target to $289 on, Nov 9th, 2020


Published on 2024-10-27 14:42:00 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $318 to $289 on, Nov 9th, 2020.

Andrew has made no other calls on BIIB in the last 4 months.



There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 5 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Colin Bristow of "UBS" Initiated at Hold and Held Target at $268 on, Wednesday, October 28th, 2020
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $282 on, Tuesday, October 27th, 2020
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $244 on, Thursday, October 22nd, 2020
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $350 on, Thursday, October 22nd, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $357 on, Thursday, October 22nd, 2020
Contributing Sources